Lataa...

Subcutaneous daratumumab and hyaluronidase-fihj in newly diagnosed or relapsed/refractory multiple myeloma

Daratumumab, a human immunoglobulin G1 kappa monoclonal antibody that targets CD38, is currently approved as monotherapy and in varying combinations with approved anti-myeloma regimens in both newly diagnosed multiple myeloma and relapsed refractory multiple myeloma. Originally developed for intrave...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Ther Adv Hematol
Päätekijät: Sanchez, Larysa, Richter, Joshua, Cho, Hearn Jay, Jagannath, Sundar, Madduri, Deepu, Parekh, Samir, Richard, Shambavi, Tam, Lowena, Verina, Daniel, Chari, Ajai
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: SAGE Publications 2021
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7841854/
https://ncbi.nlm.nih.gov/pubmed/33613930
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620720987075
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!